ImmuCell (FRA:IUL) General and Admin. Expense: €3.67 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IUL ImmuCell Corp FRA:IUL
55 GF Score
Price €8.30
GF Value €5.66
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell General and Admin. Expense?

ImmuCell FRA:IUL +1.22% 55 General and Admin. Expense is €3.67 Mil as of Jun. 2026. GuruFocus rates FRA:IUL with a GF Score™ of 55/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. ImmuCell's General and Admin. Expense for the three months ended in Jun. 2026 was €1.10 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €3.67 Mil.

ImmuCell General and Admin. Expense Related Terms

ImmuCell General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for ImmuCell's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell General and Admin. Expense Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 2.14 1.96 2.12 2.73

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.62 0.96 0.98 1.10
FRA:IUL
55GF Score
ImmuCell Corp FRA:IUL
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €3.67 Mil mean?
ImmuCell (FRA:IUL) has a General and Admin. Expense of €3.67 Mil as of Jun. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on ImmuCell and its competitors.
Is ImmuCell's General and Admin. Expense too high?
ImmuCell's current General and Admin. Expense is €3.67 Mil. Overall, ImmuCell has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's General and Admin. Expense compare to COYA and ENTX?
ImmuCell's General and Admin. Expense of €3.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on ImmuCell and its competitors. ImmuCell's current General and Admin. Expense is €3.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current General and Admin. Expense is €3.67 Mil. ImmuCell's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current General and Admin. Expense is €3.67 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (FRA:IUL) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for FRA:IUL:

  • General and Admin. Expense: €3.67 Mil
  • GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges ICCC:USA
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score

Get the complete analysis for FRA:IUL

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.30
Price
€5.66
GF Value